ERBB2 and breast carcinoma: This includes the BROCADE 3 randomized phase 3 study of the addition of veliparib or placebo to carboplatin/paclitaxel in advanced HER2-negative breast cancer patients, which demonstrated a progression free survival (PFS) benefit in the veliparib arm compared to placebo [16].